CORDIS
EU research results

CORDIS

English EN
Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria

Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria

Objective

Plasmodium vivax is the most widespread malaria and constitutes a significant proportion of human malaria cases. P. vivax accounts for 100-400 million clinical cases each year among the 2.5 billion people living at risk in Latin America, Oceania and Asia. The recently revised Malaria Vaccine Technology Roadmap to 2030 recognises the severity of P. vivax malaria and calls for a vaccine intervention to achieve 75% efficacy over two years – equally weighted with P. falciparum. However, despite this global health need, efforts to develop interventions against this parasite have lagged far behind those for P. falciparum, in large part because of critical bottlenecks in the vaccine development process. These include i) lack of assays to prioritise and down-select new vaccines due to lack of an in vitro P. vivax long-term culture system, and ii) lack of easy access to a safe controlled human malaria infection (CHMI) model to provide an early indication of vaccine efficacy in humans. The Objectives of this MultiViVax proposal will address these critical bottlenecks and shift the “risk curve” in order to better select successful vaccine candidates against multiple lifecycle stages of P. vivax:

1. We will establish a P. vivax CHMI model in Europe for the first time to facilitate the better selection of effective vaccines and remove the current bottleneck for their early-phase clinical testing.

2. We will utilise this CHMI model to identify novel antigens associated with protective blood-stage immunity in humans by taking advantage of recent advances in immuno-screening and parasite RNASeq.

3. We will progress existing vaccines targeting the current leading antigens for both the blood- and transmission-stages along the clinical development pipeline.

4. We will develop novel transgenic parasites for use in assays in order to overcome the current bottleneck in vaccine down-selection caused by the inability to culture P. vivax parasites.

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

Address

Wellington Square University Offices
Ox1 2jd Oxford

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 4 526 425,25

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

IMAXIO SA

France

EU Contribution

€ 4 126,44

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT

France

EU Contribution

€ 30 000

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 30 000

GENOME RESEARCH LIMITED

United Kingdom

EU Contribution

€ 351 298,75

EXPRES2ION BIOTECHNOLOGIES APS

Denmark

EU Contribution

€ 25 000

NOVAVAX AB

Sweden

EU Contribution

€ 56 250

OSIVAX SAS

France

EU Contribution

€ 35 873,56

Project information

Grant agreement ID: 733073

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 5 763 405

  • EU contribution

    € 5 058 974

Coordinated by:

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom